Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

10. Oktober 2017 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Presents Phase III IV Meloxicam Clinical Efficacy Data in Patients Following Abdominoplasty at the 2017 American Society of Plastic Surgeons Annual Meeting

IV Meloxicam 30mg Demonstrates Statistically Significant Reductions in Pain, Along with Reductions in Opioid Rescue Use and Improvements in Several Other Pain Relief Metrics Selected as a “Top 6”...
05. Oktober 2017 17:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma to Participate in Upcoming Investor Conferences

MALVERN, Pa., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care...
05. Oktober 2017 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Announces PDUFA Date for IV Meloxicam 30mg

MALVERN, Pa., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care...
29. September 2017 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Reports Inducement Grants for New Staff

MALVERN, Pa., Sept. 29, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care...
28. September 2017 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Announces FDA Acceptance for Review of New Drug Application for IV Meloxicam 30mg

MALVERN, Pa., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care...
05. September 2017 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Presents Phase III IV Meloxicam Clinical Safety and Opioid Use Data at PAINWeek® 2017

IV Meloxicam 30mg Demonstrates Statistically Significant Reductions in Opioid Consumption in Overall Study Population and Important Subpopulations, Including in Patients Following Major Orthopedic...
21. August 2017 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Appoints Jyrki Mattila as Executive Vice President of Business Development

MALVERN, Pa., Aug. 21, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care...
10. August 2017 15:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Reports Inducement Grants for New Staff

MALVERN, Pa., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care...
10. August 2017 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Reports Second Quarter 2017 Financial Results

Reports Second Quarter 2017 Revenues of $16.9 Million NDA Submitted to U.S. FDA for IV Meloxicam MALVERN, Pa., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue...
31. Juli 2017 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Submits New Drug Application for IV Meloxicam 30mg

MALVERN, Pa., July 31, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care...

Vorherige Seite